Seretide MDI 50/25 is a medicine containing the active ingredient(s) fluticasone propionate + salmeterol. On this page you will find out more about Seretide MDI 50/25, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: fluticasone propionate + salmeterol
Information for medicine and pack size:
Seretide MDI 50/25 pressurised inhalation, 120 actuations
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
For the regular treatment of asthma, where the use of a combination product is appropriate. This may include: *Patients on effective maintenance doses of long-acting beta-2-agonists and inhaled corticosteroids. *Patients who are symptomatic on current inhaled corticosteroid therapy.*Initiation of maintenance therapy in those patients with moderate persistent asthma not adequately controlled on "as needed" reliever medication, and who have moderate/severe airway limitation and daily symptoms requiring medication every day (See Clinical Trials). For the symptomatic treatment of patients with severe COPD (FEV1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. Seretide is not indicated for the initiation of bronchodilator therapy in COPD.
Table of characteristics
|Visual appearance||Actuator & metal can with concave base fitted with a metering valve and a plastic dose counter. The canister contains a white to off-white suspension. The internal surfaces of the can & the valve are free from obvious defects.|
|Dosage Form||Inhalation, pressurised|
|Route of administration||Inhalation|
120 doses: Prescription Only Medicine, or Prescription Animal Remedy
Sample Pack: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Type||Aerosol Can - Metered Dose|
|Storage temperature||Store below 30 degrees Celsius|
|Storage conditions||Protect from direct sunlight|
|Life time||2 Years|
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 January 2018
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.